...
首页> 外文期刊>Otology and neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology >Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph.
【24h】

Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph.

机译:地塞米松和地塞米松磷酸钠磷酸钠的内胰蛋白酶内部与静脉内递送到人工耳蜗。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To measure dexamethasone concentrations in the plasma and perilymph of the human ear after intravenous (IV) and intratympanic (IT) administration and to compare these with previous studies with methylprednisolone. METHODS: Patients were administered dexamethasone by the IT or IV routes approximately 0.5 to 2 hours before cochlear implantation. The IT dose of 1.6 to 7.2 mg (0.4-1.8 ml of a 4 mg/ml solution) of dexamethasone sodium phosphate was administered by injection into the middle ear cavity through the external auditory canal via a 27-gauge needle passed through a small anterosuperior myringotomy. The IV dose of dexamethasone sodium phosphate was 0.17 mg/kg given as a single injection for 30 seconds. A sample of perilymph (approximately 20 mul) was collected using a needle passed through the round window, and blood was sampled simultaneously. Concentrations of free dexamethasone and dexamethasone sodium phosphate were measured using a validated liquid chromatography-tandem mass spectrometry method. RESULTS: In the 22 patients studied, 22 perilymph samples and 19 plasma samples were available and suitable for measurement. The median perilymph concentration of dexamethasone after IV injection of 0.17 mg/kg was 0.016 mg/L (n = 9; range, 0.008-0.17), and 1.4 mg/L (n = 13; range, 0.1-16.3) after IT administration of approximately 4 mg. Perilymph concentrations were approximately 88-fold higher after IT compared with IV administration (p = 0.0004) or approximately 260 fold after correction for dosage. The median plasma concentration of dexamethasone after IV injection was 0.12 mg/L (n = 7; range, 0.07-0.14) and 0.003 mg/L (n = 12; range, <0.0005-0.005) after IT injection. Plasma concentrations were approximately 40-fold lower (p = 0.0005) or approximately 13-fold lower after dose correction. Concentrations of dexamethasone sodium phosphate were more variable and were even higher in perilymph and lower in plasma. CONCLUSION: Administration of dexamethasone IT results in much higher perilymph concentrations and much lower plasma concentrations compared with IV administration.
机译:目的:测量静脉内(IV)和内胰蛋白酶内(IT)给药后血浆和围膜中的地塞米松浓度,并将这些研究与先前的研究与甲基泼尼松酮进行比较。方法:在人工耳蜗植入前约0.5至2小时,通过IT或IV路线对患者进行地塞米松的治疗。通过向中耳腔,通过在中耳腔中注射到中间听觉运河中,通过向中耳腔注射通过27仪式穿过一个小前耐尖端,通过向中耳腔注射到中间腔中,通过向中耳腔注射到中间腔中给予1.6至7.2 mg(0.4-1.8 mL的4 mg/ml溶液)的磷酸钠剂量。骨髓切开术。地塞米松磷酸钠的静脉注射剂量为0.17 mg/kg,单次注射30秒。使用穿过圆形窗户的针头收集了perilymph的样品(约20mul),并同时采样血液。使用经过验证的液相色谱串联质谱法测量游离地塞米松和地塞米松钠的浓度。结果:在研究的22例患者中,可获得22个围绕permph样品和19个血浆样品,适合测量。静脉注射0.17 mg/kg后地塞米松的中位数浓度为0.016 mg/l(n = 9;范围为0.008-0.17),在其给药后,IT给药后1.4 mg/l(n = 13;范围,0.1-16.3)约4毫克。与静脉内施用相比,围ph的浓度高约88倍(p = 0.0004),剂量校正后约260倍。静脉注射后地塞米松的中位血浆浓度为0.12 mg/L(n = 7;范围为0.07-0.14)和0.003 mg/l(n = 12;范围;范围,<0.0005-0.005)。血浆浓度低约40倍(p = 0.0005),剂量校正后低约13倍。地塞米松磷酸钠的浓度变化更大,血浆中的浓度更高,血浆中的浓度更高。结论:与IV给药相比,地塞米松的给药会导致围limph浓度更高,血浆浓度更低。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号